References
- Brandt WE. From the World Health Organization. Development of dengue and Japanese encephalitis vaccines. J. Infect. Dis. 162,577–583 (1990).
- Chambers TJ, Tsai TF, Pervikov Y, Monath TP. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine 15, 1494–1502 (1997).
- Kuno G, Chang GJ, Tsuchiya KR et al. Phylogeny of the genus Flavivirus. J. Viral 72,73–83 (1998).
- Rice CM, Lenches EM, Eddy SR et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229,726–733 (1985).
- Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression and replication. Ann. Rev. Microbial. 44,649–688 (1990).
- Stadler K, Allison SL, Schalich J, Heinz FX. Proteolytic activation of tick-borne encephalitis virus by furM. J. Viral. 71, 8475–8481 (1997).
- Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M. Lethal 17D yellow fever encephalitis in mice. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Viral. 67,229-234 (1986).
- Cecilia D, Gadkari DA, Kedarnath N, Ghosh SN. Epitope mapping of Japanese encephalitis virus envelope protein using monoclonal antibodies against an Indian strain. J. Gen. Viral. 69,2741–2747 (1988).
- Zhang MJ, Wang MJ, Jiang SZ, Ma WY. Passive protection of mice, goats and monkeys against Japanese encephalitis with monoclonal antibodies. J. Med. Viral. 29, 133–138 (1989).
- Kreil TR, Maier E, Fraiss S, Eibl MM. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J. Viral. 72,3076–3081 (1998).
- Guirakhoo F, Weltzin R, Chambers TJ et al. Recombinant chimeric yellow fever dengue Type 2 virus is immunogenic and protective in nonhuman primates. J. Viral. 74,5477-5485 (2000).
- Monath TP, Levenbook I, Soike K et al. Chimeric yellow fever virus 17D Japanese encephalitis virus vaccine: dose—response effectiveness and extended safety testing in rhesus monkeys. J. ViroL 74,1742–1751 (2000).
- Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever—Japanese encephalitis virus (ChimeriVax—JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257,363–372 (1999).
- Monath TP, Soike K, Levenbook I et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (5A14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in nonhuman primates. Vaccine 17, 1869–1882 (1999).
- Butrapet S, Huang CY, Pierro DJ et al. Attenuation markers of a candidate dengue Type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J. Viral 74,3011–3019 (2000).
- Huang CY, Butrapet S, Pierro DJ et al. Chimeric dengue Type 2 (vaccine strain PDK-53)/dengue Type 1 virus as a potential candidate dengue Type 1 virus vaccine.' ViroL 74,3020–3028 (2000).
- Bray M, Lai CJ. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Nad Acad. Sci. USA 88,10342–10346 (1991).
- Barrett AD. Current status of flavivirus vaccines. Ann. 1VY Acad Sci. 951,262-271 (2001).
- Kinney RM, Huang CY. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44, 176–197 (2001).
- Nalca A, Fellows PF, Whitehouse CA. Vaccines and animal models for arboviral encephalitides. Antiviral Res. 60,153–174 (2003).
- Monath TP, Arroyo J, Miller C, Guirakhoo E West Nile virus vaccine. Curr. Drug Targets Infect. Disord. 1,37–50 (2001).
- Zanin MP, Webster DE, Martin JL, Wesselingh SL. Japanese encephalitis vaccines: moving away from the mouse brain. Expert Rev. Vaccines 2,407–416 (2003).
- Eckels KH, Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv. Virus Res. 61, 395–418 (2003).
- Lai CJ,Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis and Japanese encephalitis. Adv. Virus Res. 61,469-509 (2003). Chronicles comprehensively the history of chimeric flaviviral vaccines with an emphasis on molecular strategies.
- Putnak R, Porter K, Schmaljohn C. DNA vaccines for flaviviruses. Adv. Virus Res. 61, 445–468 (2003).
- Saluzzo JF. Empirically derived live attenuated vaccines against dengue and Japanese encephalitis. Adv. Virus Res. 61, 419–443 (2003).
- Ku CC, King CC, Lin CY et al. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J. Med Viral. 44,122–131 (1994).
- Kurane I, Takasaki T Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 18\(Suppl. 2), 33–35 (2000).
- Kuzuhara S, Nakamura H, Hayashida K et al. Nonclinical and Phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21, 4519–4526 (2003).
- Sugawara K, Nishiyama K, Ishikawa Yet al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30, 303–314 (2002).
- Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19, 4557–4565 (2001).
- Eder G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children. Vaccine 21,3575–3583 (2003).
- Baumhackl U, Franta C, Retzl J et al. A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 21, S56–561 (2003).
- Ng T, Hathaway D, Jennings N et al.Equine vaccine for west Nile virus. Dev. Bi a (Basel) 114,221–227 (2003).
- Putnak R, Barvir DA, Burrous JM et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174,1176-1184 (1996).
- Martin M, Tsai TF, Cropp B et al. Feverand multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358,98–104 (2001).
- Galler R, Pugachev KY, Santos CL et at. Phenotypic and molecular analyses of yellow fever 17D vaccine viruses associated with serious adverse events in Brazil. Viro/ogy 290,309–319 (2001).
- Pugachev KY, Ocran SW, Guirakhoo F et al. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine 20,996–999 (2002).
- Hennessy S, Liu Z, Tsai TF et al. Effectiveness of live attenuated Japanese encephalitis vaccine (SA14-14-2): a case control study. Lancet 347,1583–1586 (1996).
- Liu ZL, Hennessy S, Strom BL et al. Short- term safety of live attenuated Japanese encephalitis vaccine (5A14-14-2): results of a randomized trial with 26,239 subjects. J. Infect. Dis. 176,1366-1369 (1997).
- Bista MB, Banerjee MK, Shin SH et al. Efficacy of single dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358,791–795 (2001).
- Ma FB, Zheng L, Bi C. Study on the strategy of Japanese encephalitis immunization using live attenuated vaccine combined with inactivated vaccine (in Chinese). Zhonhua Liu Xing BingXue Za Zhi 24, 113–115 (2003).
- Kinney RM, Butrapet S, Chang GJ et al, Construction of infectious cDNA clones for dengue-2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Viro/ogy 230,300–308 (1997).
- Markoff L, Pang X, Houng HS et al. Derivation and characterization of a dengue Type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.' Vito/. 76,3318–3328 (2002).
- Lai CJ, Bray M, Men R et at. Evaluation of molecular strategies to develop a live dengue vaccine. Clin. Diagn. Virol.10, 173–179 (1998).
- Troyer JM, Hanley KA, Whitehead SS et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am. J. Trap. Med. Hyg. 65, 414–419 (2001).
- Durbin AB Karron RA, Sun Wet al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3' untranslated region. Am. J. Trap. Med. Hyg 65,405–413 (2001).
- Rabablert J, Dharakul T, Yoksan S, Bhamarapravati N. Dengue virus specific T-cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines. Asian Pac. J. Allergy Immund 18,227–235 (2000).
- Kanesa-Thasan N, Sun W, Kim-Ahn G et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179–3188 (2001). Describes safety, clinical responses, and immunogenicity in human volunteers immunized with a live, tetravalent dengue vaccine.
- Edelman R, Wasserman SS, Bodison SA et al. Phase I trial of 16 formulations of a tetravalent live attenuated dengue vaccine. Am. J. Trap. Med. Hyg. 69,48-60 (2003).
- Davidson I, Lachmi BE, Weisman Y. Development of RT-PCR for turkey meningoencephalitis virus and partial sequence analysis of the N55 gene. Virus Genes 16,211–224 (1998).
- Lustig S, Olshevsky U, Ben-Nathan D et al. A live attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immund 13,401–410 (2000).
- Konishi E, Kurane I, Mason PW et al. Induction of Japanese encephalitis virus-specific cytotoxic T-lymphocytes in humans by poxvirus-based JE vaccine candidates. Vaccine 16,842–849 (1998).
- Raengsakulrach B, Nisalak A, Gettayacamin M et al. Safety, immunogenicity and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. Am. J. Trap. Med Hyg. 60,343–349 (1999).
- Kanesa-Thasan N, Smucny JJ, Hoke CH et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19, 483–491 (2000).
- Nam JH, Cha SL, Cho HW. Immunogenicity of a recombinant MVA and a DNA vaccine for Japanese encephalitis virus in swine. Microbial Immund 46,23–28 (2002).
- Gallwitz S, Schutzbank T, Heberling RL et al. Smallpox: residual antibody after vaccination. J. Clin. Microbial. 41, 4068–4070 (2003).
- Stephenson J. Defective adenoviruses as novel vaccines for the Flaviviridae. Clin. Di agn. Viral 10,187–194 (1998).
- Jaiswal S, Khanna N, Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus Type 2. J. Viral. 77,12907-12913 (2003).
- Jacobs SC, Stephenson JR, Wilkinson GW. High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model." Vito/. 66,2086-2095 (1992).
- Timofeev AV, Ozherelkov SV, Pronin AV et al. A recombinant adenovirus expressing the nsl nonstructural protein of tick-borne encephalitis virus: some characteristics of the immunologic basis of antiviral action. Vopr. Virusol 42,219–222 (1997).
- Lundstrom K. Alphavirus-based vaccines. Curr. Opin. Mal. The?: 4,28-34 (2002).
- Pugachev KY, Mason PW, Frey TK. Sindbis vectors suppress secretion of subviral particles ofJapanese encephalitis virus from mammalian cells infected with SIN-JEV recombinants. Virology 209,155–166 (1995).
- Rolls MM, Webster P, Balba NH, Rose JK. Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. Cell 79,497–506 (1994).
- Morris-Downes MM, Sheahan BJ, Fleeton MN et al. A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine 19,3877–3884 (2001).
- Fleeton MN, Liljestrom P, Sheahan BJ, Atkins GJ. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J. Gen. Viral. 81,749–758 (2000).
- Colombage G, Hall R, Pavy M, Lobigs M. DNA-based and alphavirus-vectored immunization with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250,151–163 (1998).
- Simmons M, Porter KR, Escamilla J et al. Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies. Am. J. Trap. Med Hyg. 58, 144–151 (1998).
- Simmons M, Murphy GS, Kochel T et at. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trap. Med Hyg. 65,420-426 (2001).
- Hermida L, Rodriguez R, Lazo L et at. A recombinant envelope protein from dengue virus purified by IMAC is bioequivalent with its immune—affinity chromatography purified counterpart. J. Biotechnol. 94, 213–216 (2002).
- Guzman MG, Rodriguez R, Rodriguez R et aL Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am. J. Trap. Med Hyg 69,129–134 (2003).
- Bisht H, Chugh DA, Raje M et al. Recombinant dengue virus Type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. J. BiotechnoL 99,97–110 (2002).
- Staropoli I, Clement JM, Frenkiel MP et al. Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein. J. Viral. Methods 56, 179–189 (1996).
- Staropoli I, Frenkiel MP, Megret F, Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 15,1946–1954 (1997).
- Kelly EP, Greene JJ, King AD, Innis BL. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18,2549–2559 (2000).
- Bielefeldt-Ohmann H, Beasley DW, Fitzpatrick DR, Aaskov JG. Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system. J. Gen. ViroL 78,2723–2733 (1997).
- Saini M, Vrati S. A Japanese encephalitis virus peptide present on johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J. Viral. 77, 3487–3494 (2003).
- Konishi E, Pincus S, Paoletti E et al. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188,714–720 ( 1992).
- Konishi E, Pincus S, Fonseca BA et aL Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology 185,401–410 (1991).
- Allison SL, Stadler K, Mandl CW et al. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Viral. 69, 5816–5820 (1995).
- Aberle JH, Aberle SW, Allison SL et at. A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J. Immunol. 163, 6756–6761 (1999).
- Allison SL, Stiasny K, Stadler K et al. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J. Viral. 73,5605–5612 (1999).
- Chang GJ, Hunt AR, Holmes DA et al. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus Type 2 and Japanese encephalitis virus. Virology 306,170–180 (2003).
- ••Improved approaches to enhance secretionof viral proteins and induction of higher protective antibodies titer in immunized mice are described.
- Davis BS, Chang GJ, Cropp B et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Viral. 75, 4040–4047 (2001).
- Chang GJ, Hunt AR, Davis B. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J. Vird 74,4244–4252 (2000).
- Ferlenghi I, Clarke M, Ruttan T et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mal. Cell7, 593–602 (2001).
- Konishi E, Fujii A. Dengue Type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20,1058–1067 (2002).
- Konishi E, Fujii A, Mason PW. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J. Viral. 75,2204–2212 (2001).
- Gehrke R, Ecker M, Aberle SW et al. Incorporation of tick-borne Encephalitis virus replicons into virus-like particles by a packaging cell line. J. ViroL 77, 8924–8933 (2003).
- Hunt AR, Cropp CB, Chang GJ. A recombinant particulate antigen ofJapanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J. ViroL Methods 97,133–149 (2001).
- Kojima A, Yasuda A, Asanuma H et at. Stable high producer cell clone expressing virus-like particles of the Japanese encephalitis virus E protein for a second generation subunit vaccine. J. Viral. 77, 8745–8755 (2003).
- Boyer JC, Haenni AL. Infectious transcripts and cDNA clones of RNA viruses. Virology 198,415–426 (1994).
- Ruggli N, Rice CM. Functional cDNA clones of the Flaviviridae: strategies and applications. Adv. Virus Res. 53,183–207 (1999).
- Pugachev KV, Guirakhoo F, Ocran SW et aL High fidelity of yellow fever virus RNA polymerase. I ViroL 78,1032–1038 (2004).
- Whitehead SS, Falgout B, Hanley KA et al. A live, attenuated dengue virus Type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.' Vird. 77,1653–1657 (2002).
- Men R, Bray M, Clark D et al. Dengue Type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Viral. 70,3930-3937 (1996).
- Hall RA, Nisbet DJ, Pham KB et al. DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of west Nile virus. Proc. Natl Acad. Sci. 100, 10460–10464 (2003).
- •Application of an attenuated Kunjin virus full-length infectious clone as a DNA vaccine against WNV is an interesting concept.
- Prikhod'ko GG, Prikhodlo EA, Cohen JI, Pletnev AG. Infection with Langat Flavivirus or expression of the envelope protein induces apoptotic cell death. Virology 286,328-335 (2001).
- Mandl CW, Aberle JH et al. In vitro synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat. Med. 4,1438–1440 (1998).
- Kofler RM, Aberle JH, Aberle SW et al. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc. Natl Acad. Sci. USA101,1951–1956 (2004).
- Lai CJ, Zhao BT, Hon i Bray, H. M. Infectious RNA transcribed from stably cloned full-length cDNA of dengue Type 4 virus. Proc. Natl Acad Sci. USA 88, 5139–5143 (1991).
- Huang CY, Butrapet S, Tsuchiya KR et d. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.' ViroL 77,11436–11447 (2003).
- Butrapet S, Rabablert J, Angsubhakorn S et al. Chimeric dengue Type 2/type 1 viruses induce immune responses in cynomolgus monkeys. Southeast Asian J. Trap. Med. Public Health 33,589–599 (2002).
- Guirakhoo F, Arroyo J, Pugachev KY et al. Construction, safety and immunogenicity in nonhuman primates of a chimeric yellow fever—dengue virus tetravalent vaccine. J. Viral. 75,7290–7304 (2001).
- Arroyo J, Guirakhoo F, Fenner S et al. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax—JE). J. Viral. 75, 934–942 (2001).
- Chambers TJ, Liang Y, Droll DA et al. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity and protection against dengue encephalitis in the mouse model. J. Viral. 77,3655-3668 (2003).
- Johnson BW, Chambers TV, Crabtree MB et al. Growth characteristics of ChimeriVax—DENV-2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am. J. Trap. Med. Hyg. 67, 260–265 (2002).
- Guirakhoo F, Pugachev K, Arroyo J et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment and antibody responses against wild type dengue virus isolates. Virology 298, 146–159 (2002).
- van Der Most RG, Murali-Krishna K, Ahmed R, Strauss JH. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Viral. 74, 8094–8101 (2000).
- Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. ViroL 73, 3095–3101 (1999).
- Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20, 1004–1018 (2002).
- ••The efficacy and safety of chimeric vaccinecandidates using YFV backbone.
- Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbial. Immunol. 267,105–138 (2002).
- Monath TP, Guirakhoo F, Nichols R et at. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase II clinical trials for safety and immunogenicity, effect of vaccine dose and schedule and memory response to challenge with inactivated Japanese encephalitis antigen.' Infect. Dis. 188,1213-1230 (2003).
- Pletnev AG, Bray M, Huggins J, Lai CJ. Construction and characterization of chimeric tick-borne encephalitis—dengue Type 4 viruses. Proc. Natl Acad. Sci. USA 89,10532–10536 (1992).
- Pletnev AG, Bray M, Lai CJ. Chimeric tick-borne encephalitis and dengue Type 4 viruses: effects of mutations on neurovirulence in mice. J. Viral. 67, 4956–4963 (1993).
- Pletnev AG, Bray M, Hanley KA et al. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J. Viral. 75,8259–8267 (2001).
- Pletnev AG, Claire MSt, Elkins R et al. Molecularly engineered live attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 314,190–195 (2003).
- Pletnev AG, Putnak R, Speicher J et al. West Nile virus/dengue Type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl Acad. Sci. USA 99,3036–3041 (2002).
- Johnson BW, Chambers TV, Crabtree MB et al. Growth characteristics of the veterinary vaccine candidate ChimeriVax-west Nile (WN) virus in Aedes and Culex mosquitoes. Med. Vet. Entomol. 17, 235–243 (2003).
- Monath TP. Prospects for development of a vaccine against the West Nile virus. Ann. 1VY Acad. Sci. 951,1-12 (2001).
- Arroyo J, Miller CA, Catalan J, Monath TP. Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mal. Med. 7,350–354 (2001).
- Langevin SA, Arroyo J, Monath TP, Komar N. Host range-restriction of chimeric yellow fever West Nile vaccine in fish crows (Corvus ossifiugus). Am. J. Trap. Med. Hyg 69,78–80 (2003).
- Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann. Rev. Immunol. 15, 617–648 (1997).
- Donnelly JJ, Liu MA, Ulmer JB. Antigen presentation and DNA vaccines. Am. J. &Or. Cris. Care Med 162, S190—S193 (2000).
- Chang GJ, Davis BS, Hunt AR et al. Flavivirus DNA vaccines: current status and potential. Ann. 1VY Acad. Sci. 951,272-285 (2001).
- ••A more scientific-based approach to designrecombinant plasmid as DNA vaccines, rather than trial and error methods, was presented for the first time.
- Schmaljohn C, Custer D, VanderZanden L et al. Evaluation of tick-borne encephalitis DNA vaccines in monkeys. Virology 263, 166–174 (1999).
- Jan LR, Yang CS, Henchal LS et al. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxy—terminal truncation of Japanese encephalitis virus envelope glycoprotein. Am. J. Trap. Med Hyg. 48, 412–423 (1993).
- Raviprakash K, Kochel TJ, Ewing D et al. Immunogenicity of dengue virus Type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18, 2426–2434 (2000).
- Jacobs M,Young P. Dengue vaccines: preparing to roll back dengue. Curr. Opin. Investig. Drugs 4,168–171 (2003).
- Wu SF, Liao CL, Lin YL et al. Evaluation of protective efficacy and immune mechanisms of using a nonstructural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21, 3919–3929 (2003).
- Chen HW, Pan CH, Liau MY et al. Screening of protective antigens ofJapanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. J. Viral. 73,10137–10145 (1999).
- Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch. Viral. 142, 897–916 (1997).
- Lin CF, Lei HY, Shiau AL et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J. Immuna 169,657–664 (2002).
- Konishi E, Yamaoka M, Kurane I, Mason PW. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B-cells and long lasting antibodies in swine. Virology 268,49–55 (2000).
- Konishi E, Yamaoka M, Khin SW et at. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Viral. 72, 4925–4930 (1998).
- Lin YL, Chen LK, Liao CL et al. DNA immunization with Japanese encephalitis virus nonstructural protein NS/ elicits protective immunity in mice. J. Viral. 72, 191–200 (1998).
- Ashok MS, Rangarajan PN. Evaluation of the potency of BIKEN inactivated Japanese encephalitis vaccine and DNA vaccines in an intracerebral Japanese encephalitis virus challenge. Vaccine 19,155–157 (2000).
- Wu CJ, Huang HW, Tao MH. Induction of cross protection against two wild type Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine. Vaccine 21,3938–3945 (2003).
- Lobigs M, Pavy M, Hall R. Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 21, 1572–1579 (2003).
- Phillpotts RJ, Venugopal K, Brooks T Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. Arch. Viral. 141,743–749 (1996).
- Heinz FX. Molecular aspects of TBE virus research. Vaccine 21,53–510 (2003).
- Schmaljohn C, Vanderzanden L, Bray M et al. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J. ViroL 71,9563–9569 (1997).
- Morozova OV, Maksimova TG, Bakhvalova VN. Tick-borne encephalitis virus NS3 gene expression does not protect mice from homologous viral challenge. Viral Immuna 12,277–280 (1999).
- Turell MJ, Bunning M, Ludwig GV et al. DNA vaccine for West Nile virus infection in fish crows (Corvus ossifragus). Emerg. Infect. Dis. 9,1077–1081 (2003).
- Innis BL, Eckels KH. Progress in development of a live attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am. J. Trap. Med. Hyg. 69,1–4 (2003).
- Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J. ViroL 73,783–786 (1999).
- An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse model for dengue virus infection. Virology 263,70–77 (1999).
- Blaney JE Jr, Johnson DH, Manipon GG et al. Genetic basis of attenuation of dengue virus Type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300,125–139 (2002).
- Lin YL, Liao CL, Chen LK et al. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Viral. 72, 9729–9737 (1998).
- Wu SJ, Hayes CG, Dubois DR et al. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am. J. Trap. Med. Hyg 52,468–476 (1995).
- Tesh RB, Arroyo J, Travassos Da Rosa AP et al. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect. Dis. 8,1392–1397 (2002).
- •The importance of a wide range of choice of animal models for evaluating vaccine efficacy is emphasized.
- Leyssen P, Croes R, Rau P et al. Acute encephalitis, a poliomyelitis-like syndrome and neurological sequelae in a hamster model for flavivirus infections. Brain Pathol. 13,279–290 (2003).
- Marchevsky RS, Freire MS, Coutinho ESF, Galler R. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316,55–63 (2003).
- Raengsakulrach B, Nisalak A, Gettayacamin M et al. An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys. Am. J. Trap. Med. Hyg 60,329–337 (1999).
- Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of tetravalent live attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am. J. Trap. Med. Hyg 66,264–272 (2002).
- Monath TP, Arroyo J, Levenbook I et al. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. ViroL 76, 1932–1943 (2002).
- Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18\(Suppl. 2), 26–32 (2000).
- Ashok MS, Rangarajan PN. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies. Vaccine 18,68–75 (1999).
- Kuno G. Serodiagnosis of flaviviral infections and vaccinations in humans. Adv. Virus Res. 61,3–65 (2003).
- Buckley A, Dawson A, Moss SR et al. Serological evidence of West Nile virus, Usutu virus and Sindbis virus infection of birds in the UK. J. Gen. ViroL 84, 2807–2817 (2003).
- Nusbaum KE, Wright JC, Johnston W13 et al. Absence of humoral response in flamingos and red-tailed hawks to experimental vaccination with a killed West Nile virus vaccine. Avian Dis. 47,750-752 (2003).
- Watanaveeradej V, Endy TP, Samakoses R et al. Transplacentally transferred maternal—infant antibodies to dengue virus. Am. J. Trop. Med. Hyg. 69,123–128 (2003).
- Rojanasuphot S, Shaffer N, Chotpitayasunondh T et al. Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian Trap. Med. Public Health. 29, 443–450 (1998).
- Panasiuk B, Prokopowicz D, Panasiuk A. Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection 31,45–46 (2003).
- Sibailly TS, Wiktor SZ, Tsai TF et al. Poor antibody response to yellow fever vaccination in children infected with HIV Type 1. Pediatr. Infect. Dis.J. 16, 1177–1179 (1997).
- Zent 0, Jilg W, Plentz A et al. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule. Vaccine 21, 4655–4660 (2003).
- Marth E, Kleinhappl B. Albumin is a necessary stabilizer of TBE vaccine to avoid fever in children after vaccination. Vaccine 20,532–537 (2001).
- Hussain AT, Johnson JA, da Silva Freire M, Heneine W. Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J. ViroL 77,1105–1111 (2002).
- Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of a three dose regimen of two tetravalent live attenuated dengue vaccines in 5-12-year-old Thai children. Pediatr. Infect. Dis. J. 23, 99–109 (2004).
- Dowdle VTR, De Gourville E, Kew OM et al. Polio eradication: the OPV paradox. Rev. Med. Viral. 13,277–291 (2003).
- Mor G, Eliza M. Plasmid DNA vaccines. Immunology, tolerance and autoimmunity. Md. Biotechnd. 19,245–250 (2001).
- Ledwith BJ, Manam S, Troilo PJ et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. kiterviro/ogy 43, 258–272 (2000).
- Parker SE, Borellini F, Wenk ML et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum. Gene The?: 10,741–758 (1999).
- Gilbert PB, Chiu YL, Allen M et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21, 2933–2947 (2003).
- Le TP, Coonan KM, Hedstrom RC et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18, 1893–1901 (2000).
- Epstein JE, Gorak EJ, Charoenvit Yet al. Safety, tolerability and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection and comparison of intramuscular and combination intramusculadintradermal routes. Hum. Gene Ther. 13, 1551–1560 (2002).
- Price WH, Thind IS. Protection against west Nile virus induced by a previous injection with dengue virus. Am. J. Epidemiol 94,596–607 (1971).
- Goverdhan MK, Kulkarni AB, Gupta AK et al. Two-way cross-protection between west Nile and Japanese encephalitis viruses in bonnet macaques. Acta Viral. 36,277–283 (1992).
- Tesh RB, Travassos da Rosa AP, Guzman H et al. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect. Dis. 8, 245–251 (2002).
- Kochel TJ, Watts DM, Halstead SB et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360, 310–312 (2002).
- Sabin AB. Research on dengue during World War II. Am. J. Trap. Med. Hyg 1, 30–50 (1952).
- Bi P, Tong S, Donald K et al. Climate variability and transmission of Japanese encephalitis in eastern China. Vector Borne Zoonotic Dis. 3,111–115 (2003).
- Sabin AB. Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control. Eur. J. Epidemiol 7, 1–22 (1991).
- Endy TP, Nisalak A, Chunsuttitwat S et al Relationship of pre-existing dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.' Infect. Dis. 189,990–1000 (2004).
- Abstracts of a scientific meeting Dengue virus: Molecular basis of cell entry and pathogenesis. Vienna, Austria, June 25–27, (2003).
Websites
- Website of the Center for Biological Sequence Analysis. http://www.cbs.dtu.dldservices/SignalP/ Accessed March, 2004.